Obsidian Energy Ltd. (OBE)
NYSEAMERICAN: OBE · Real-Time Price · USD
5.90
-0.22 (-3.59%)
Aug 1, 2025, 4:00 PM - Market closed
CTI BioPharma Stock Forecast
Stock Price Forecast
The 2 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $11.5, which forecasts a 94.92% increase in the stock price over the next year. The lowest target is $9.00 and the highest is $14.
Price Target: $11.50 (+94.92%)
Analyst Consensus: Buy
* Price targets were last updated on May 8, 2025.
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $10 → $9 | Hold | Maintains | $10 → $9 | +52.54% | May 8, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $12 → $10 | Buy → Hold | Downgrades | $12 → $10 | +69.49% | Apr 17, 2025 |
| Raymond James | Raymond James | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +137.29% | Oct 18, 2024 |
Financial Forecast
Revenue This Year
611.56M
from 731.20M
Decreased by -16.36%
Revenue Next Year
624.69M
from 611.56M
Increased by 2.15%
EPS This Year
0.57
from -2.67
EPS Next Year
n/a
from 0.57
Financial currency is CAD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | 703.5M | 809.6M |
| Avg | 611.6M | 624.7M |
| Low | 530.2M | 456.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | -3.8% | 32.4% |
| Avg | -16.4% | 2.1% |
| Low | -27.5% | -25.3% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | 0.59 | - |
| Avg | 0.57 | - |
| Low | 0.55 | - |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.